Use of Immunotherapy for HCC – OncLive
|
Use of Immunotherapy for HCC
OncLive Transcript: Catherine T. Frenette, MD: How do you choose which patients would be appropriate for immunotherapy? Darren S. Sigal, MD: So, right now, in the second-line setting, we have 2 approved options. One is regorafenib, based on the RESORCE trial, … |
